Robert Bartlett - Cytosorbents Crp Chief Medical Officer
| CTSO Stock | USD 0.81 0.01 1.22% |
Executive
Dr. Robert Hawes Bartlett, M.D., is Chief Medical Officer of CytoSorbents Corporationration, since January 2009. He is Professor Emeritus of Surgery at the University of Michigan Health System. Prior to becoming Professor Emeritus in 2005, Dr. Bartlett was Director of the Surgical Intensive Care Unit, Chief of the TraumaClinical Care Division and Director of the Extracorporeal Life Support Program at the University of Michigan Medical Center. Dr. Bartlett was the pioneer in the development of the extracorporeal membrane oxygenation machine, used to oxygenate blood in critically ill patients worldwide. He received his MD from the University of Michigan Medical School, cum laude. He completed his general surgery residency at Peter Bent Brigham Hospital in Boston, and was Chief resident in thoracic surgery. Dr. Bartlett was also a NIH Trainee in Academic Surgery at Harvard Medical School, and was previously faculty at the University of California, Irvine since 2009.
| Age | 71 |
| Tenure | 15 years |
| Address | 305 College Road East, Princeton, NJ, United States, 08540 |
| Phone | 732 329 8885 |
| Web | https://www.cytosorbents.com |
Cytosorbents Crp Management Efficiency
The company has return on total asset (ROA) of (0.3248) % which means that it has lost $0.3248 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9721) %, meaning that it created substantial loss on money invested by shareholders. Cytosorbents Crp's management efficiency ratios could be used to measure how well Cytosorbents Crp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of May 2024, Return On Tangible Assets is likely to drop to -0.61. In addition to that, Return On Capital Employed is likely to grow to -0.75. At this time, Cytosorbents Crp's Total Assets are very stable compared to the past year. As of the 1st of May 2024, Non Current Assets Total is likely to grow to about 28.9 M, while Total Current Assets are likely to drop about 17.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chen Zhang | Aesthetic Medical Intl | N/A | |
| Jim Brown | HCA Holdings | N/A | |
| Chad Wasserman | HCA Holdings | N/A | |
| Kathleen JD | HCA Holdings | 60 | |
| MD MBA | HCA Holdings | 58 | |
| Mark Palmenter | Acadia Healthcare | N/A | |
| Gretchen Hommrich | Acadia Healthcare | N/A | |
| Isa Diaz | Acadia Healthcare | N/A | |
| Bill Priest | Acadia Healthcare | N/A | |
| Frank CFA | HCA Holdings | N/A | |
| Nasser MD | Acadia Healthcare | N/A | |
| Kirk Cheney | Pennant Group | N/A | |
| Emily Mattacchione | Novo Integrated Sciences | 43 | |
| Martin Paslick | HCA Holdings | 64 | |
| Heather CPA | Acadia Healthcare | 52 | |
| Terence Arkel | HCA Holdings | N/A | |
| Laura Groschen | Acadia Healthcare | N/A | |
| Lyn Ketelsen | HCA Holdings | N/A | |
| Klara Radulyne | Novo Integrated Sciences | 38 | |
| Michael Marks | HCA Holdings | 53 | |
| Qing Hu | Aesthetic Medical Intl | 60 | |
Management Performance
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.32 |
Cytosorbents Crp Leadership Team
Elected by the shareholders, the Cytosorbents Crp's board of directors comprises two types of representatives: Cytosorbents Crp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytosorbents. The board's role is to monitor Cytosorbents Crp's management team and ensure that shareholders' interests are well served. Cytosorbents Crp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytosorbents Crp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathleen Bloch, CFO | ||
| CPA CPA, CFO Sec | ||
| Alan Sobel, Director | ||
| Michael Bator, Director | ||
| Phillip Chan, President CEO, Director | ||
| MS MS, Pres COO | ||
| Christian MD, Executive Marketing | ||
| Vincent MS, President COO | ||
| FACC FESC, Chief Officer | ||
| Vincent Capponi, COO | ||
| James Gunton, Independent Director | ||
| Jodi Hoover, Executive | ||
| Robert MD, CoChairman Consultant | ||
| Edward Jones, Independent Director | ||
| MS MBA, Senior Development | ||
| Terri MBA, Vice Communications | ||
| Irina Kulinets, Senior Affairs | ||
| Eric Mortensen, Chief Medical Officer | ||
| Al Kraus, Chairman of the Board | ||
| Robert Bartlett, Chief Medical Officer |
Cytosorbents Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cytosorbents Crp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.32 | ||||
| Profit Margin | (0.78) % | ||||
| Operating Margin | (1.02) % | ||||
| Current Valuation | 47.94 M | ||||
| Shares Outstanding | 54.31 M | ||||
| Shares Owned By Insiders | 9.37 % | ||||
| Shares Owned By Institutions | 38.01 % | ||||
| Number Of Shares Shorted | 1.55 M | ||||
| Price To Earning | (16.30) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cytosorbents Crp in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cytosorbents Crp's short interest history, or implied volatility extrapolated from Cytosorbents Crp options trading.
Pair Trading with Cytosorbents Crp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytosorbents Crp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytosorbents Crp will appreciate offsetting losses from the drop in the long position's value.Moving together with Cytosorbents Stock
| 0.7 | AHG | Akso Health Group | PairCorr |
Moving against Cytosorbents Stock
| 0.76 | GCTK | GlucoTrack | PairCorr |
| 0.69 | SNDA | Sonida Senior Living | PairCorr |
| 0.64 | TNDM | Tandem Diabetes Care | PairCorr |
| 0.61 | TLIS | Talis Biomedical Corp | PairCorr |
| 0.52 | JYNT | Joint Corp Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Cytosorbents Crp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytosorbents Crp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytosorbents Crp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytosorbents Crp to buy it.
The correlation of Cytosorbents Crp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytosorbents Crp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytosorbents Crp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytosorbents Crp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Cytosorbents Stock analysis
When running Cytosorbents Crp's price analysis, check to measure Cytosorbents Crp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytosorbents Crp is operating at the current time. Most of Cytosorbents Crp's value examination focuses on studying past and present price action to predict the probability of Cytosorbents Crp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytosorbents Crp's price. Additionally, you may evaluate how the addition of Cytosorbents Crp to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Cytosorbents Crp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share 0.814 | Quarterly Revenue Growth (0.08) | Return On Assets (0.32) | Return On Equity (0.97) |
The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.